Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.

"Conflict of interest statement MR reports that Public Health England provided financing for the epidemiological evaluation of the English HPV pilot; being a member of Public Health England's Laboratory Technology Group, HPV Self-sampling Operational Steering Group, and HPV Self-sampling Project Board; having attended meetings with various HPV assay manufacturers; fee for lecture from Hologic paid to employer (2018). KC reports that she is co-principal investigator of an unrelated investigator-initiated trial of cervical screening in Australia (Compass; ACTRN12613001207707 and NCT02328872), which is conducted and funded by the VCS Foundation (VCS), a government-funded health promotion charity. The VCS Foundation received equipment and a funding contribution from Roche Molecular Systems USA. However, neither KC nor her institution on her behalf (Cancer Council NSW) receives direct funding from industry for this trial or any other project. All other authors: no conflicts to declare."

"Funding This work was supported by the 10.13039/501100000925National Health and Medical Research Council (Australia; grant APP1159491 to MAS), Cancer Council NSW (MH, XO), 10.13039/501100000289Cancer Research UK (grant number C8162/A27047 to AC and MR), 10.13039/501100001171Cancer Institute NSW (ECF181561 to MAS), 10.13039/100000002National Institutes of Health (USA; U01CA199334 to EAB and JK), 10.13039/100008730Norwegian Cancer Society (#198073 to EAB). These funders had no role in the study design; collection, analysis and interpretation of data; the writing of the manuscript; or the decision to submit."